gip/glp-1 agonist New strategies for the treatment of obesity and metabolic dysfunctions Possible mechanisms of action of

Anyone with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take GLP 1 medications

While Byetta is not a weight loss medication, participants lost an average of 6 to 6.4 pounds

Any future GLP-1 lawsuit settlement will likely depend on the plaintiffs diagnosis, objective medical evidence, treatment history, permanency of the injury, and the overall impact the complications had on daily life and employment

The impact of obesity on IBD onset and progression is an area of growing research, though evidence remains controversial

Available at: (Accessed August 9, 2022)

Supplementary Information Below is the link to the electronic supplementary material